This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication

reputable news agency


Erenumab effective, safe for rosacea-linked erythema, flushing

Credit: Unsplash/CC0 Public Domain

The anticalcitonin gene-related peptide-receptor monoclonal antibody erenumab is effective and safe for treatment of rosacea-associated erythema and flushing, according to a study published in JAMA Dermatology.

Nita K.F. Wienholtz, M.D., Ph.D., from Copenhagen University Hospital-Rigshospitalet in Denmark, and colleagues examined the effectiveness, tolerability, and safety of erenumab for treatment of rosacea-associated erythema and flushing in a single-center, nonrandomized trial involving adults with rosacea with at least 15 days of moderate-to-severe erythema and/or moderate-to-extreme flushing. Participants received 140 mg erenumab subcutaneously every four weeks for a period of 12 weeks; safety was assessed at week 20.

Thirty participants were included; 27 completed the study. The researchers observed a reduction of −6.9 days in the mean number of days with moderate-to-extreme flushing, from 23.6 days at baseline. For moderate-to-severe erythema, the mean number of days was reduced by −8.1 from 15.2 at baseline. Adverse events included transient mild-to-moderate constipation, transient worsening of flushing, bloating, and upper respiratory tract infection (33, 13, 10, and 10%, respectively). One participant discontinued the study due to a serious adverse event, deemed unrelated to the study, and two withdrew consent due to .

"The results also suggest that erenumab is generally well tolerated, with mild and/or transient adverse effects," the authors write. "Larger randomized, controlled, double-blind studies are necessary to confirm these findings and to investigate the long-term effects of erenumab ."

A related Editor's Note in JAMA Dermatology appears here.

More information: Nita K. F. Wienholtz et al, Erenumab for Treatment of Persistent Erythema and Flushing in Rosacea, JAMA Dermatology (2024). DOI: 10.1001/jamadermatol.2024.0408

John S. Barbieri, Potential Role of Calcitonin Gene-Related Peptide Inhibitors in the Treatment of Rosacea Flushing and Erythema, JAMA Dermatology (2024). DOI: 10.1001/jamadermatol.2024.0397

Journal information: JAMA Dermatology

2024 HealthDay. All rights reserved.

Citation: Erenumab effective, safe for rosacea-linked erythema, flushing (2024, April 17) retrieved 30 May 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Bioactive retinol efficacious for improving signs of photoaging


Feedback to editors